McBayne Tyrone O, Siddall O'Rita M
College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125-1098, USA.
Ann Pharmacother. 2006 May;40(5):939-42. doi: 10.1345/aph.1G006. Epub 2006 May 2.
To review clinical trial data to determine the benefits of using montelukast alone or as combination therapy in the treatment of urticaria.
MEDLINE (1966-March 2006) and International Pharmaceutical Abstracts (1970-October 2005) were searched to find clinical trial publications that addressed the use of montelukast in urticaria.
Six clinical trials were identified. Montelukast was compared alone and as combination therapy with nonsedating histamine1-receptor antagonists to determine efficacy and safety. Patients had chronic or physical urticaria. The results were mixed. Some studies demonstrated that montelukast can decrease urticarial symptoms with minimal adverse effects, while others found no differences.
Large-scale, controlled trials are needed to determine which patients would likely benefit from treatment with montelukast.
回顾临床试验数据，以确定单独使用孟鲁司特或作为联合疗法治疗荨麻疹的益处。
检索MEDLINE（1966年 - 2006年3月）和国际药学文摘（1970年 - 2005年10月），以查找涉及孟鲁司特在荨麻疹治疗中应用的临床试验出版物。
确定了六项临床试验。将孟鲁司特单独使用以及与非镇静性组胺1受体拮抗剂联合使用进行比较，以确定疗效和安全性。患者患有慢性或物理性荨麻疹。结果不一。一些研究表明孟鲁司特可减轻荨麻疹症状且不良反应最小，而其他研究则未发现差异。
需要进行大规模对照试验，以确定哪些患者可能从孟鲁司特治疗中获益。
